Cargando…
Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear β-catenin expression
Up to 60% of gastro-oesophageal junction (GEJ) adenocarcinomas show nuclear β-catenin expression, pointing to activated T-cell factor (TCF)/β-catenin-driven gene transcription. We demonstrate in five human GEJ adenocarcinoma cell lines that nuclear β-catenin expression indeed correlates with enhance...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215949/ https://www.ncbi.nlm.nih.gov/pubmed/14970870 http://dx.doi.org/10.1038/sj.bjc.6601589 |
_version_ | 1782216446912233472 |
---|---|
author | Koppert, L B van der Velden, A W van de Wetering, M Abbou, M van den Ouweland, A M W Tilanus, H W Wijnhoven, B P L Dinjens, W N M |
author_facet | Koppert, L B van der Velden, A W van de Wetering, M Abbou, M van den Ouweland, A M W Tilanus, H W Wijnhoven, B P L Dinjens, W N M |
author_sort | Koppert, L B |
collection | PubMed |
description | Up to 60% of gastro-oesophageal junction (GEJ) adenocarcinomas show nuclear β-catenin expression, pointing to activated T-cell factor (TCF)/β-catenin-driven gene transcription. We demonstrate in five human GEJ adenocarcinoma cell lines that nuclear β-catenin expression indeed correlates with enhanced TCF-mediated transcription of a reporter gene. In several tumour types, TCF/β-catenin activation is caused by mutations in either adenomatous polyposis coli (APC), β-catenin exon 3, AXIN1, AXIN2 or β-transducin repeat-containing protein (β-TrCP). In GEJ adenocarcinomas, very few APC and β-catenin mutations have been found. Therefore, the mechanism of Wnt pathway activation remains unclear. In the present study, we did not find AXIN1 gene mutations in 17 GEJ tumours with nuclear β-catenin expression (without β-catenin exon 3 mutations). Six intragenic single nucleotide polymorphisms (SNPs) were identified. One of these, the AXIN1 gene T1942C SNP, has a frequency of 21% but is only very recently described despite numerous AXIN1 gene mutational studies. We provide evidence why this SNP was missed in single strand conformation polymorphism analyses. The AXIN1 gene G2063A variation was previously described as a gene mutation but we demonstrate that this is a polymorphism. With these six SNPs loss of heterozygosity (LOH) was found in 11 of 15 (73%) informative tumours. To investigate a possible AXIN1 gene dosage effect in GEJ tumours expressing nuclear β-catenin, AXIN1 locus LOH was determined in 20 tumours expressing membranous and no nuclear β-catenin. LOH was found in 10 of 13 (77%) informative cases. AXIN1 protein immunohistochemistry revealed cytoplasmic expression in all tumours irrespective of the presence of AXIN1 locus LOH. These data indicate that nuclear β-catenin expression is indicative for activated Wnt signalling and that neither AXIN1 gene mutations nor AXIN1 locus LOH are involved in Wnt pathway activation in GEJ adenocarcinomas. |
format | Online Article Text |
id | pubmed-3215949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-32159492011-12-28 Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear β-catenin expression Koppert, L B van der Velden, A W van de Wetering, M Abbou, M van den Ouweland, A M W Tilanus, H W Wijnhoven, B P L Dinjens, W N M Br J Cancer Genetics and Genomics Up to 60% of gastro-oesophageal junction (GEJ) adenocarcinomas show nuclear β-catenin expression, pointing to activated T-cell factor (TCF)/β-catenin-driven gene transcription. We demonstrate in five human GEJ adenocarcinoma cell lines that nuclear β-catenin expression indeed correlates with enhanced TCF-mediated transcription of a reporter gene. In several tumour types, TCF/β-catenin activation is caused by mutations in either adenomatous polyposis coli (APC), β-catenin exon 3, AXIN1, AXIN2 or β-transducin repeat-containing protein (β-TrCP). In GEJ adenocarcinomas, very few APC and β-catenin mutations have been found. Therefore, the mechanism of Wnt pathway activation remains unclear. In the present study, we did not find AXIN1 gene mutations in 17 GEJ tumours with nuclear β-catenin expression (without β-catenin exon 3 mutations). Six intragenic single nucleotide polymorphisms (SNPs) were identified. One of these, the AXIN1 gene T1942C SNP, has a frequency of 21% but is only very recently described despite numerous AXIN1 gene mutational studies. We provide evidence why this SNP was missed in single strand conformation polymorphism analyses. The AXIN1 gene G2063A variation was previously described as a gene mutation but we demonstrate that this is a polymorphism. With these six SNPs loss of heterozygosity (LOH) was found in 11 of 15 (73%) informative tumours. To investigate a possible AXIN1 gene dosage effect in GEJ tumours expressing nuclear β-catenin, AXIN1 locus LOH was determined in 20 tumours expressing membranous and no nuclear β-catenin. LOH was found in 10 of 13 (77%) informative cases. AXIN1 protein immunohistochemistry revealed cytoplasmic expression in all tumours irrespective of the presence of AXIN1 locus LOH. These data indicate that nuclear β-catenin expression is indicative for activated Wnt signalling and that neither AXIN1 gene mutations nor AXIN1 locus LOH are involved in Wnt pathway activation in GEJ adenocarcinomas. Nature Publishing Group 2004-02-23 2004-02-17 /pmc/articles/PMC3215949/ /pubmed/14970870 http://dx.doi.org/10.1038/sj.bjc.6601589 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Genetics and Genomics Koppert, L B van der Velden, A W van de Wetering, M Abbou, M van den Ouweland, A M W Tilanus, H W Wijnhoven, B P L Dinjens, W N M Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear β-catenin expression |
title | Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear β-catenin expression |
title_full | Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear β-catenin expression |
title_fullStr | Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear β-catenin expression |
title_full_unstemmed | Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear β-catenin expression |
title_short | Frequent loss of the AXIN1 locus but absence of AXIN1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear β-catenin expression |
title_sort | frequent loss of the axin1 locus but absence of axin1 gene mutations in adenocarcinomas of the gastro-oesophageal junction with nuclear β-catenin expression |
topic | Genetics and Genomics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215949/ https://www.ncbi.nlm.nih.gov/pubmed/14970870 http://dx.doi.org/10.1038/sj.bjc.6601589 |
work_keys_str_mv | AT koppertlb frequentlossoftheaxin1locusbutabsenceofaxin1genemutationsinadenocarcinomasofthegastrooesophagealjunctionwithnuclearbcateninexpression AT vanderveldenaw frequentlossoftheaxin1locusbutabsenceofaxin1genemutationsinadenocarcinomasofthegastrooesophagealjunctionwithnuclearbcateninexpression AT vandeweteringm frequentlossoftheaxin1locusbutabsenceofaxin1genemutationsinadenocarcinomasofthegastrooesophagealjunctionwithnuclearbcateninexpression AT abboum frequentlossoftheaxin1locusbutabsenceofaxin1genemutationsinadenocarcinomasofthegastrooesophagealjunctionwithnuclearbcateninexpression AT vandenouwelandamw frequentlossoftheaxin1locusbutabsenceofaxin1genemutationsinadenocarcinomasofthegastrooesophagealjunctionwithnuclearbcateninexpression AT tilanushw frequentlossoftheaxin1locusbutabsenceofaxin1genemutationsinadenocarcinomasofthegastrooesophagealjunctionwithnuclearbcateninexpression AT wijnhovenbpl frequentlossoftheaxin1locusbutabsenceofaxin1genemutationsinadenocarcinomasofthegastrooesophagealjunctionwithnuclearbcateninexpression AT dinjenswnm frequentlossoftheaxin1locusbutabsenceofaxin1genemutationsinadenocarcinomasofthegastrooesophagealjunctionwithnuclearbcateninexpression |